权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immunotherapeutic targeting of MIF-dependent chaperone activity

MIF 依赖性伴侣活性的免疫治疗靶向

基本信息

批准号：
10633912
负责人：
ROBERT A MITCHELL
金额：
$ 35.59万
依托单位：
UNIVERSITY OF LOUISVILLE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-04-01 至 2028-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10633912
关键词：
ALS patients Acute Antibody Therapy Binding Biological Assay Biological Availability CTLA4 gene Cell Lineage Cell surface Cells Clinic Clinical Communities Cuprozinc Superoxide Dismutase Data Disease Progression Disease Resistance Drug Targeting Effector Cell Functional disorder Future Gene Expression Profile Genetic Transcription Homeostasis Human Hypoxia Immune Immune checkpoint inhibitor Immunosuppression Immunotherapeutic agent Immunotherapy In complete remission Individual Innate Immune Response Laboratories Lead Lesion Macrophage Malignant - descriptor Malignant Neoplasms Metabolic Metastatic Melanoma Migration Inhibitory Factor Mitochondria Modality Molecular Chaperones Monoclonal Antibodies Myelogenous Myeloid Cell Activation Myeloid Cells Myeloid-derived suppressor cells Neoplasm Metastasis Oral Pathway interactions Patients Phenocopy Phenotype Physiological Play Proteins Respiration Role Solid Solid Neoplasm Stromal Cells Structure-Activity Relationship Suicide Superoxide Dismutase T-Lymphocyte Testing Therapeutic Tissue-Specific Gene Expression Transgenic Organisms Tumor-associated macrophages analog angiogenesis antagonist anti-CTLA4 anti-CTLA4 antibodies anti-PD-1 anti-PD1 antibodies cancer immunotherapeutics cancer therapy combinatorial cytokine endoplasmic reticulum stress immune checkpoint blockade immunogenic immunoregulation improved inhibitor melanoma mitochondrial dysfunction monocyte mouse model mutant neovascularization neurotoxicity novel overexpression partial response polarized cell prevent programmed cell death protein 1 protein folding receptor response small molecule small molecule inhibitor stressor tumor tumor microenvironment tumor progression tumorigenic

项目摘要

PROJECT SUMMARY “Immunotherapeutic targeting of MIF-dependent chaperone activity” Metabolic reprogramming that favors mitochondrial respiration plays an important role in controlling differential gene expression patterns in myeloid lineage cells. Our recent findings have identified a novel protein chaperone-dependent pathway that indirectly controls mitochondrial homeostasis and metabolic programming that are needed to drive maximal intratumoral myeloid cell immune suppressive phenotypes. Our hypothesis predicts that small molecule inhibition of this chaperone activity, carried out by the multifunctional cytokine MIF, induces spontaneous Cu/Zn superoxide dismutase (SOD1) misfolding and aberrant mitochondrial binding leading to metabolic reprogramming and subsequent phenotypic reversion of intratumoral myeloid cell immune suppressive phenotypes into immune stimulatory phenotypes. Studies proposed in this application will: 1) Delineate the mechanisms of action of 4-IPP-based MIF chaperone inhibitors in the context of MIF/SOD1- dependent TAM/MDSC polarization; 2) Determine the relative contribution of hypoxia as a physiologic ER stressor that exacerbates myeloid wt SOD1 misfolding in the context of MIF and 4-IPP, and 3) Evaluate the therapeutic potential of lead MIF chaperone antagonists as individual and combinatorial modalities against established metastatic melanoma.

项目总结 “MIF依赖的伴侣活性的免疫治疗靶向” 有利于线粒体呼吸的代谢重编程在控制中发挥着重要作用髓系细胞的差异基因表达模式。我们最近的发现发现了一种新的蛋白质间接控制线粒体动态平衡和代谢编程的伴侣依赖途径这是驱动最大的肿瘤内髓系细胞免疫抑制表型所需的。我们的假设预测由多功能细胞因子MIF执行的对这种伴侣活性的小分子抑制，诱发自发性铜锌超氧化物歧化酶(SOD1)错误折叠和线粒体结合异常导致代谢重新编程和随后的瘤内髓细胞免疫表型逆转抑制表型转变为免疫刺激表型。本申请书建议的研究将：1) 阐明了4-IPP为基础的MIF伴侣抑制剂在MIF/SOD1-中的作用机制依赖/mdsc极化；2)确定低氧作为生理性内质网的相对贡献在MIF和4-IPP的背景下，加剧髓系Wt SOD1错误折叠的应激源，以及3)评估铅MIF伴侣拮抗剂作为单独和联合治疗的潜力确诊为转移性黑色素瘤。